Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Official citation and/or docket number and footnotes (if any) for this case available with purchase.

Learn more about what you receive with purchase of this case.

In re Yasmin and Yaz Marketing

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF ILLINOIS


September 3, 2010

IN RE YASMIN AND YAZ (DROSPIRENONE) MARKETING, SALES PRACTICES AND RELEVANT PRODUCTS LIABILITY LITIGATION

The opinion of the court was delivered by: Hon. David R. Herndon

This Document Applies To All Actions

MDL No. 2100

DEFENDANTS' SUPPLEMENTAL FACT SHEET

I. CASE INFORMATION

This DFS Supplement pertains to the following case:

Case caption:

____________________________________________________

Civil Action No.

_________________________________________________

Court in which action was originally filed:

______________________________

Date that this DFS Supplement was completed:

__________________________________

II. SALES REPRESENTATIVE OR DETAIL PERSON SUPPLEMENTAL INFORMATION

1. For each Sales Representative or detail person that had contact with each Dispensing/Prescribing Healthcare Providers identified in Section II(B)(2) of the DFS, please provide the following information for a period of one (1) year before he/she began covering the earliest Dispensing/Prescribing Health Care Provider identified in the PFS for Yaz, Yasmin, Ocella, premenstrual syndrome, premenstrual dysphoric disorder or acne to one (1) year after he/she concluded covering that Dispensing/Prescribing Health Care Provider for Yaz, Yasmin, Ocella, premenstrual syndrome, premenstrual dysphoric disorder or acne:

Name of Sales Representative/Detail Person Salary Bonus Regional Rank District Rank National Rank

2. For each Sales Representative or detail person identified in Section II(B)(2) of the DFS, please identify and produce pursuant to Section III, below, all employee performance evaluations, periodic review reports, self-reviews, comparative sales ranking reports, and any other evaluation of the employee's sales performance maintained in the Sales Representative's personnel file or the Sales Representative's custodial file (or maintained by the Sales Representative's supervisors) for a period of one (1) year before he/she began covering the earliest Dispensing/Prescribing Health Care Provider identified in the PFS for Yaz, Yasmin, Ocella, premenstrual syndrome, premenstrual dysphoric disorder or acne to one (1) year after he/she concluded covering the latest Dispensing/Prescribing Health Care Provider identified in the PFS for Yaz, Yasmin, Ocella, premenstrual syndrome, premenstrual dysphoric disorder or acne.

___________________________________________________________ ___________________________________________________________

3. For Each Sales Representative or detail person identified in Section II

(B)(2) of the DFS that had contact with each Dispensing/Prescribing Healthcare Providers, identify any visual aids or other materials tracked by the ENGAGE system that were shown by the Sales Representative or detail person to each dispensing/Prescribing Healthcare Providers identified in Section IX of the PFS during any sales call when Yaz, Yasmin, or Ocella was discussed. Also, attach (a) a copy of such visual aids and (b) provide a copy of all data from the ENGAGE system that reflects or relates to the showing of any visual aid to the Dispensing/Prescribing Healthcare Providers.

4. Please identify the person or persons who provided information responsive to Section II or any of its subparts.

___________________________________________________________ ___________________________________________________________

III. DOCUMENTS

A. To the extent you have not already done so, please produce a copy of all documents and things in your possession, custody and control that fall into the categories listed below, for each Sales Representative or detail person identified in Section II (B) (2) of the DFS (for a period of one (1) year before he/she began covering the earliest Dispensing/Prescribing Health Care Provider identified in the PFS for Yaz, Yasmin, Ocella, premenstrual syndrome, premenstrual dysphoric disorder or acne to one (1) year after he/she concluded covering that Dispensing/Prescribing Health Care Provider for Yaz, Yasmin, Ocella, premenstrual syndrome, premenstrual dysphoric disorder or acne. These documents shall be produced pursuant to the schedule set forth in the CMO implementing this Defendants' Supplemental Fact Sheet:

1) Any document signed by the Sales Representative or detail person acknowledging the Defendants' business or ethics practices or policies;

2) Any personnel or performance review, evaluation, critique, reward or actions plans related to the performance of the Sales Representative or detail person by a Superior;

3) Any self-review, self-evaluation, self-critique, action plans by the Sales Representative or detail person created as part of any formal policy;

4) Any document evidencing periodic reviews of performance or sales of the Sales Representative or detail person;

5) Any document reflecting comparative sales ranking of the Sales Representative or detail person;

6) Any documents reflecting any award given to the Sales Representative or detail person;

7) Any documents reflecting incentive plans based on sales of oral contraceptives for the Sales Representative or detail person;

8) Documents sufficient to establish the compensation of the Sales Representative or detail person including:

a. Salary

b. Bonus, and,

c. Other rewards or compensation such as trips, dinners, or gift-cards.

DECLARATION

I am authorized to make this Declaration on behalf of ______________________. The information provided in the foregoing Defendant Fact Sheet has been compiled by employees and legal counsel for ________________________. Although I do not have personal knowledge of all of the information set forth therein, I declare under penalty of perjury, pursuant to 28 U.S.C. Sec. 1746, that the foregoing is true and correct to the best of my knowledge, understanding and belief, formed after due diligence and reasonable inquiry. _____________________ _____________________

__________________ Signature Print Name Date

20100903

© 1992-2010 VersusLaw Inc.



Buy This Entire Record For $7.95

Official citation and/or docket number and footnotes (if any) for this case available with purchase.

Learn more about what you receive with purchase of this case.